Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response

Journal of Immunotherapy

Volumn 33, Issue 9, 2010, Pages 935-944

  Bourquin, Carole ^a   Wurzenberger, Cornelia ^a   Heidegger, Simon ^a   Fuchs, Sebastian ^c   Anz, David ^b   Weigel, Sarah ^a   Sandholzer, Nadja ^a   Winter, Gerhard ^c   Coester, Conrad ^c   Endres, Stefan ^a  

^a Munich Center for Integrated Protein Science   (Germany)

^b Department of Internal Medicine ^*  (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

delivery; nanoparticles; RNA oligonucleotides; Toll like receptor 7; tumor immunotherapy

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; GAMMA INTERFERON; GELATIN; INTERLEUKIN 12; LIPOFECTAMINE; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; POLYETHYLENEIMINE; RIBONUCLEASE; RNA OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CARCINOMA; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENDOSOME; ENZYME DEGRADATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; INNATE IMMUNITY; MELANOMA; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GELATIN; IMMUNITY, HUMORAL; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES; RNA; TOLL-LIKE RECEPTOR 7;

EID: 78149281913     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f5dfa7     Document Type: Article

References (34)

1. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529.
2. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
3. Hornung V, Ellegast J, Kim S, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314:994-997.
4. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101-105.
5. Anz D, Thaler R, Stephan N, et al. Activation of melanoma differentiation-associated gene 5 causes rapid involution of the thymus. J Immunol. 2009;182:6044-6050.
6. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184-1194.
7. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimula-tory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997;94:10833-10837.
8. Wurzenberger C, Koelzer VH, Schreiber S, et al. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunol Immunother. 2009;58:901-913.
9. +T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115:739-746.
10. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11:263-270.
11. Bourquin C, Schmidt L, Lanz AL, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol. 2009;183:6078-6086.
12. Poeck H, Besch R, Maihoefer C, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008;14:1256-1263.
13. Bourquin C, Schmidt L, Hornung V, et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood. 2007;109:2953-2960.
14. Janke M, Poth J, Wimmenauer V, et al. Selective and direct activation of human neutrophils but not eosinophils by Tolllike receptor 8. J Allergy Clin Immunol. 2009;123:1026-1033.
15. Berger M, Ablasser A, Kim S, et al. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J Immunother. 2009;32:262-271.
16. Anz D, Koelzer V, Moder S, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol. 2009;183:6078-6086.
17. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
18. Broomfield SA, van der Most RG, Prosser AC, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009;182:5217-5224.
19. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-138.
20. Zwiorek K, Bourquin C, Battiany J, et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimula-tory effects of CpG oligonucleotides. Pharm Res. 2008;25:551-562.
21. Ward AG, Courts A. The Science and Technology of Gelatin. New York: Academic Press; 1977.
22. Coester CJ, Langer K, van Briesen H, et al. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencap-sul. 2000;17:187-193.
23. Bourquin C, Anz D, Zwiorek K, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol. 2008;181:2990-2998.
24. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur J Pharm Biopharm. 2006;62:306-314.
25. Ablasser A, Poeck H, Anz D, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol. 2009;182:6824-6833.
26. Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33:439-447.
27. Lan T, Kandimalla ER, Yu D, et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci U S A. 2007;104:13750-13755.
28. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature. 2009;457:426-433.
29. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531.
30. Yasuda K, Yu P, Kirschning CJ, et al. Endosomal transloca-tion of vertebrate DNA activates dendritic cells via TLR9-dependent and-independent pathways. J Immunol. 2005;174:6129-6136.
31. Bouxsein NF, McAllister CS, Ewert KK, et al. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry. 2007;46:4785-4792.
32. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122-1126.
33. Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A. 2009;106:870-875.
34. +T-cell responses in nonhuman primates. Proc Natl Acad Sci U S A. 2005;102:15190-15194.